TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells (Q39319003)

11 September 2017

title

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells (English)

1 reference

11 September 2017

0 references

0 references

mesenchymal stem cell

1 reference

1 reference

M R Moniri

1

1 reference

11 September 2017

X-Y Sun

2

1 reference

11 September 2017

J Rayat

3

1 reference

11 September 2017

D Dai

4

1 reference

11 September 2017

Z Ao

5

1 reference

11 September 2017

Z He

6

1 reference

11 September 2017

C B Verchere

7

1 reference

11 September 2017

L-J Dai

8

1 reference

11 September 2017

G L Warnock

9

1 reference

11 September 2017

publication date

6 July 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

652-658

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2012.46

11 September 2017

exact match

0 references

cites work

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Potential implications of mesenchymal stem cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

TRAIL as a target in anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Impedance measurement for real time detection of neuronal cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

Preoperative staging and assessment of resectability of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

inferred from DOI database lookup

7 January 2021

based on heuristic

The xCELLigence system for real-time and label-free monitoring of cell viability

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.46

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2012.46

1 reference

Dimensions Publication ID

11 September 2017

1047657453

0 references

1 reference